Publication

Severe, fatal multisystem manifestations in a patient with dolichol kinase-congenital disorder of glycosylation

Downloadable Content

Persistent URL
Last modified
  • 06/25/2025
Type of Material
Authors
    Michelle T Lieu, University of California Los AngelesBobby G Ng, Sanford Burnham Medical Research InstituteJeffrey S Rush, University of KentuckyTim Wood, Greenwood Genetic CenterMonica J Basehore, Greenwood Genetic CenterMadhuri Hegde, Emory UniversityRichard C Chang, CHOC Childrens SpecialistsJose E Abdenur, CHOC Childrens SpecialistsHudson H Freeze, Sanford Burnham Medical Research InstituteRaymond Y Wang, CHOC Childrens Specialists
Language
  • English
Date
  • 2013-12-01
Publisher
  • Elsevier: 12 months
Publication Version
Copyright Statement
  • © 2013 Elsevier Inc.
License
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 1096-7192
Volume
  • 110
Issue
  • 4
Start Page
  • 484
End Page
  • 489
Grant/Funding Information
  • This work was supported by The Rocket Fund and by R01 DK55615 (HHF).
Abstract
  • Congenital disorders of glycosylation are a group of metabolic disorders with an expansive and highly variable clinical presentation caused by abnormal glycosylation of proteins and lipids. Dolichol kinase (DOLK) catalyzes the final step in biosynthesis of dolichol phosphate (Dol-P), which is the oligosaccharide carrier required for protein N-glycosylation. Human DOLK deficiency, also known as DOLK-CDG or CDG-Im, results in a syndrome that has been reported to manifest with dilated cardiomyopathy of variable severity. A male neonate born to non-consanguineous parents of Palestinian origin presented with dysmorphic features, genital abnormalities, talipes equinovarus, and severe, refractory generalized seizures. Additional multi-systemic manifestations developed including dilated cardiomyopathy, hepatomegaly, severe insulin-resistant hyperglycemia, and renal failure, which were ultimately fatal at age 9. months. Electrospray ionization mass spectrometric (ESI-MS) analysis of transferrin identified a type I congenital disorder of glycosylation; next-generation sequencing demonstrated homozygous p.Q483K DOLK mutations that were confirmed in patient fibroblasts to result in severely reduced substrate binding and catalytic activity. This patient expands the phenotype of DOLK-CDG to include anatomic malformations and multi-systemic dysfunction.
Author Notes
Keywords
Research Categories
  • Health Sciences, Medicine and Surgery
  • Chemistry, Biochemistry
  • Biology, Genetics

Tools

Relations

In Collection:

Items